ClinicalTrials.gov PRS DRAFT Receipt (Working Version)
Last Update: 03/02/2016 09:07
ClinicalTrials.gov ID: NCT02493634

Study Identification

Unique Protocol ID: N4IPMCF2015
Brief Title: Post-market Clinical Follow-up Study With Magnetic Resonance Imaging Conditional Guide Wire (MRWIREPMCF)
Official Title: Post-market Clinical Follow-up Study With Magnetic Resonance Imaging Conditional Guide Wire
Secondary IDs:

Study Status

Record Verification: February 2016
Overall Status: Recruiting
Study Start: August 2015
Primary Completion: June 2016 [Anticipated]
Study Completion: August 2016 [Anticipated]

Sponsor/Collaborators

Sponsor: Nano4Imaging GmbH
Responsible Party: Sponsor
Collaborators: CERES GmbH

Oversight

FDA Regulated?: No
IND/IDE Protocol?: No
Review Board: Approval Status: Approved
Approval Number: 254/14
Board Name: Ethikkommission, Medical Faculty
Board Affiliation: Technical University Munich
Phone: +498941404371
Email: info@ek.med.tum.de
Data Monitoring?: No
Plan to Share Data?: Undecided
Oversight Authorities: Germany: Ethics Commission
Study Description

Brief Summary: This is post-market clinical follow-up study on 25 consecutive patients in two centers to evaluate the safety and performance of magnetic resonance imaging conditional guide wire and the acceptability of identified risks in the clinical evaluation and to detect emerging risks on the basis of factorial evidence. The procedure will be done in patients with a clinical indication for cardiac magnetic resonance and conventional catheterisation.

Detailed Description: This is post-market clinical follow-up study on 25 consecutive patients in two centers to evaluate the safety of a guide wire conditional for use in magnetic resonance imaging and the acceptability of identified risks in the clinical evaluation and to detect emerging risks on the basis of factorial evidence.

The guidewire is used to access the patient's central circulatory system and in particular for the introduction and exact placement of a pressure catheter to measure the pressure gradient over the aortic arch. The procedure will be done in patients with a clinical indication for cardiac magnetic resonance and conventional catheterisation. Patients need to have a body weight over 40 kg and the introduction of a 5 French catheter should be possible. The primary endpoint is the measurement of procedural success, defined as successful insertion, steerability and visibility in MRI, in the absence of device-related adverse events such as damage to vessel wall. In addition, structural integrity of the instruments is to be assessed.

Conditions

Conditions: Congenital Heart Defect

Keywords: Magnetic Resonance spectroscopy
             Aortic Arch

Study Design

Study Type: Interventional
Primary Purpose: Diagnostic
Study Phase: N/A
Intervention Model: Single Group Assignment
Number of Arms: 1
   Masking: Single Blind (Outcomes Assessor)
   Allocation: N/A
Endpoint Classification: Safety/Efficacy Study
Enrollment: 25 [Anticipated]

⚠️ WARNING: Masking 'Single Blind' implies that this is a multi-arm study, but only one arm has been specified.

Arms and Interventions

<table>
<thead>
<tr>
<th>Arms</th>
<th>Assigned Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>pressure gradient measurement</td>
<td>Procedure/Surgery: pressure gradient measurement in series of patients. Focus is on safety and absence of adverse events</td>
</tr>
<tr>
<td>Diagnostic procedure to measure pressure gradient</td>
<td>A guidewire is used to introduce and position a pressure catheter under magnetic resonance</td>
</tr>
<tr>
<td>Arms</td>
<td>Assigned Interventions</td>
</tr>
<tr>
<td>------</td>
<td>------------------------</td>
</tr>
<tr>
<td></td>
<td>guidance to conduct flow and pressure measurement in the aortic arch to evaluate vascular resistance.</td>
</tr>
<tr>
<td></td>
<td>Other Names:</td>
</tr>
<tr>
<td></td>
<td>• MRWire</td>
</tr>
<tr>
<td></td>
<td>Device: MRWire</td>
</tr>
</tbody>
</table>

**NOTE**: Intervention Description: data not entered.

**NOTE**: Intervention 'MRWire' has not been included in any Arm/Group Descriptions.

### Outcome Measures

**Primary Outcome Measure:**

1. Procedural success

   [Time Frame: Up to 30 days after procedure] [Safety Issue: Yes]

   Procedural success means that insertion, steerability and visibility of the guide wire in the MR guided intervention was successfully reached, in the absence of adverse events up to 30 days after procedure.

### Eligibility

**Minimum Age:**

**Maximum Age:**

**Gender:** Both

**Accepts Healthy Volunteers?**: No

**Criteria**

**Inclusion Criteria:**

- patients with clinical indication for cardiac magnetic resonance and conventional diagnostic catheterisation
- patients with body weight of > 40 kg in which the introduction of an introducer of > 5 French is possible.
- subject provided written informed consent using the approved consent form or in case of a minor the subject provided written assent and its legal guardian provided written informed consent.

**Exclusion Criteria:**

- major surgery in the last 42 days
- history of irreversible bleeding disorder
- contraindication to cardiac magnetic resonance
- Contraindications to guidewire procedures, such as evidence of active infection
- women of child-bearing potential who cannot provide a negative pregnancy test
- chronic total occlusion.

### Contacts/Locations

**Central Contact:** Paul Borm, Prof, PhD  
Telephone: +4915222578848  
Email: paul.borm@nano4imaging.com

**Central Contact Backup:** Christoph Manegold, MBA  
Telephone: +491717704392  
Email: cm@nano4imaging.com

**Study Officials:** Peter Ewert, Prof, MD  
Study Principal Investigator
German Heart centre-Munich

Locations: Germany
Herzzentrum Leipzig
[Recruiting]
Leipzig, Germany, 04289
Contact: Ingo Daehnert, Prof, MD +49 3418651036 ingo.daehnert@med.uni-leipzig.de
Contact: Jacqueline Richter +49 341865 1445 jacqueline.richter@medizin.uni-leipzig.de

Deutsches Herzzentrum Munchen
[Recruiting]
Munich, Bavaria, Germany, 80636
Contact: Christian meierhofer, PD, MD +49-8912181070 meierhofer@dhm.mhn.de
Contact: Peter Ewert, Prof., MD +498912183011 ewert@dhm.mhn.de

United Kingdom
Royal Free Hospital- Great Ormond Street Hospital
[Not yet recruiting]
London, United Kingdom, WC1N 1EH
Contact: Vivek Muthurangu, PhD, MD +442074059200 Ext. 5556 v.muthurangu@ucl.ac.uk
Contact: Daniel Knight, MD +447881956240 danielknight@doctors.org.uk

References

Citations:


Links:
Study Data/Documents: